Literature DB >> 11466055

Estrogen-derived steroidal metal complexes: agents for cellular delivery of metal centers to estrogen receptor-positive cells.

A Jackson1, J Davis, R J Pither, A Rodger, M J Hannon.   

Abstract

Targeted cellular delivery of drugs to specific tissues is an important goal in biomedical chemistry. Achieving this requires harnessing and applying molecular-level recognition events prevalent in (or specific to) the desired tissue type. Tissues rich in estrogen receptors (ERs), which include many types of breast cancer, accumulate molecules that have high binding affinities for these receptors. Therefore, molecules that (i) bind to the ER, (ii) have favorable cellular transport properties, and (iii) contain a second functionality (such as a center that may be used for diagnostic imaging or medical therapy) are exciting synthetic targets in the field of drug delivery. To this end, we have prepared a range of metallo-estrogens based on 17alpha-ethynylestradiol and examined their binding to the ER both as isolated receptor and in whole cell assays (ER positive MCF-7 cells). Estrogens functionalized with metal binding units are prepared by palladium-catalyzed cross-coupling reactions and a wide range of metal centers introduced readily. All the compounds prepared and tested exhibit effective binding to the estrogen receptor and are delivered across the cell membrane into MCF-7 cells. In the whole cell assays, despite their monocationic nature, the palladium and platinum complexes prepared exhibit similar (and even enhanced) receptor binding affinities compared to their corresponding neutral free ligands. It is unprecedented for a higher ER binding affinity to be observed for a cationic complex than for its metal-free ligand.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11466055     DOI: 10.1021/ic010152a

Source DB:  PubMed          Journal:  Inorg Chem        ISSN: 0020-1669            Impact factor:   5.165


  9 in total

1.  Targeting the estrogen receptor with metal-carbonyl derivatives of estradiol.

Authors:  Robert N Hanson; Rein Kirss; Emmett McCaskill; Edward Hua; Pakamas Tongcharoensirikul; Sandra L Olmsted; David Labaree; Richard B Hochberg
Journal:  Bioorg Med Chem Lett       Date:  2012-01-08       Impact factor: 2.823

2.  A bifunctional platinum(II) antitumor agent that forms DNA adducts with affinity for the estrogen receptor.

Authors:  Eunsuk Kim; Peter T Rye; John M Essigmann; Robert G Croy
Journal:  J Inorg Biochem       Date:  2008-10-26       Impact factor: 4.155

3.  Non-traditional platinum compounds for improved accumulation, oral bioavailability, and tumor targeting.

Authors:  Katherine S Lovejoy; Stephen J Lippard
Journal:  Dalton Trans       Date:  2009-10-01       Impact factor: 4.390

4.  In vivo magnetic resonance imaging of the estrogen receptor in an orthotopic model of human breast cancer.

Authors:  Adi Pais; Chidambaram Gunanathan; Raanan Margalit; Inbal Eti Biton; Ady Yosepovich; David Milstein; Hadassa Degani
Journal:  Cancer Res       Date:  2011-10-31       Impact factor: 12.701

5.  Selective estrogen receptor modulator delivery of quinone warheads to DNA triggering apoptosis in breast cancer cells.

Authors:  Kuan-Wei Peng; Huali Wang; Zhihui Qin; Gihani T Wijewickrama; Meiling Lu; Zhican Wang; Judy L Bolton; Gregory R J Thatcher
Journal:  ACS Chem Biol       Date:  2009-12-18       Impact factor: 5.100

Review 6.  Exploring the cellular accumulation of metal complexes.

Authors:  Cindy A Puckett; Russell J Ernst; Jacqueline K Barton
Journal:  Dalton Trans       Date:  2009-12-23       Impact factor: 4.390

7.  Investigation of aromatase inhibitory activity of metal complexes of 8-hydroxyquinoline and uracil derivatives.

Authors:  Veda Prachayasittikul; Ratchanok Pingaew; Chanin Nantasenamat; Supaluk Prachayasittikul; Somsak Ruchirawat; Virapong Prachayasittikul
Journal:  Drug Des Devel Ther       Date:  2014-08-14       Impact factor: 4.162

Review 8.  Rationally Designed Ruthenium Complexes for Breast Cancer Therapy.

Authors:  Golara Golbaghi; Annie Castonguay
Journal:  Molecules       Date:  2020-01-09       Impact factor: 4.411

9.  Estrogen Receptor-Targeted Contrast Agents for Molecular Magnetic Resonance Imaging of Breast Cancer Hormonal Status.

Authors:  Adi Pais; Hadassa Degani
Journal:  Front Oncol       Date:  2016-04-27       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.